COVID-19 (SARS-CoV-2) RT-PCR Assay

We are proud to play an active role in the fight against COVID-19. Our services are designed to:

Support healthcare providers by keeping their employees safe and testing patients
Assist educational institutions with reopening and protecting the health of individuals
Help businesses reopen their workplaces and keep employees and customers safe
Enable government to keep their local and regional communities safe, including residents at long term care facilities, and others
Help individuals with testing on affordable basis

TaqPathTM COVID-19 Combo Kit contains the assays and controls for a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid (RNA) from SARS-CoV-2 in upper respiratory specimens in acute phase of infection
Sample types bronchoalveolar lavage (BAL), mid-turbinate swabs, nasal swabs, nasopharyngeal swabs, nasopharyngeal aspirate (nasal aspirate), and oropharyngeal swabs (see Fig 1).
Assays target three coronavirus genes: orf-1ab, S, and N having higher specificity with lower risk for mutation.
Each run covers 94 specimens in 3 hours allowing turnaround (from sample receipt to report) within 24-48 hours.
Positive results are indicative of the presence of SARS-CoV-2 RNA. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
Intended use under Food and Drug Administration’s Emergency Use Authorization limited to Clinical Laboratory certified under CLIA 88.